Adaptimmune Therapeutics PLC
ADAPY- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001621227
No open-market purchases or sales by Adaptimmune Therapeutics PLC insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Adaptimmune Therapeutics PLC changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 55 | 10 | −45 |
| Shares | 42.1M | 1.66M | −40.4M (−96.1%) |
| Value | $5.47M | $79.7K | −$5.39M (−98.5%) |
New holders (1)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Josh Arnold Investment Consultant, LLC | 20,000 | $37.8K | 0.03% |
Sold out (46)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q3 2025 and filed for Q4 2025 without it.